PERBANDINGAN KUALITAS HIDUP PENDERITA GAGAL JANTUNG KRONIK YANG MENDAPATKAN TERAPI ANGIOTENSIN CONVERTING ENZYME INHIBITORS ATAU ANGIOTENSIN II RESEPTOR BLOCKERS DENGAN β-BLOCKERDAN TANPA β-BLOCKER DI RSUP Dr SARDJITO

DWI PUMP YETTYNINGSIH, Ika Puspita Sari, M.Si., Ph.D., Apt.

2013 | Tesis | S2 Ilmu Farmasi

Gagal jantung merupakan tahap akhir dari seluruh penyakit jantung dan merupakan penyebab peningkatan morbiditas dan mortalitas penderita penyakit jantung. Tujuan utama pengobatan gagal jantung kronik adalah mengurangi gejala, memperbaiki kualitas hidup serta memperpanjang harapan hidup. Tujuan penelitian mengetahui perbedaan kualitas hidup penderita gagal jantung kronik di RSUP Dr. Sardjito Yogyakarta yang mendapatkan terapi ACEI (angiotensinconverting enzyme inhibitor) atau ARB (angiotensin II receptor blocker) dengan β-blocker dibandingkan tanpa β-blocker dengan menggunakan kuesioner spesifik MLHF (Minnesota Living with Heart Failure). Penelitian Cohort Retrospective dengan melakukan consecutive sampling selama periode November 2012 – Maret 2013. Data kualitas hidup dikumpulkan dari hasil pengisian kuesioner MLHF saat penderita gagal jantung kronik secara acak datang kontrol di rumah sakit, satu bulan setelah mendapatkan terapi ACEI atau ARB dengan β-blocker dan tanpa β-blocker. Analisa data dengan sistem skoring, uji validitas dan reliabilitas, Chi Square test, independen T test, dan analisis regresi linear. Karakteristik 112 subyek penelitian (masing-masing kelompok 56 responden). Hasil penelitian terdapat hubungan yang bermakna antara komorbid penderita gagal jantung pada kelompok responden yang diterapi ACEI atau ARB dengan β-blocker dan kelompok yang diterapi tanpa β-blocker (0,014 ≤ 0,05). Dilanjutkan analisis regresi linear, penderita dengan ≥ 2 komorbid didapatkan hasil signifikan pada kelompok responden yang diterapi ACEI atau ARB dengan β-blocker terhadap kualitas hidupnya (0,032 ≤ 0,05). Hubungan terapi dengan kualitas hidup melalui independen T test diperoleh ada perbedaan bermakna kualitas hidup antara kelompok responden yang diterapi ACEI atau ARB dengan β-blocker dan tanpa β-blocker (0,046 ≤ 0,05).

The aim of study is to find out the difference in the quality of life in patient with chronic heart failure Dr. Sardjito Central General Hospital, treated who were a either β-blocker, ACEI, ARB theraphy at compare to those who were treated with either ACEI or ARB. The study is a method Cohort Retrospective, using a consecutive sampling method, during November 2012 – March 2013. Quality of life from outpatient data was collected based on MLHF (Minnesota Living with Heart Failure) questionnaire chronic heart failure patient , randomly came to the hospital from outpatient care (a month after they were given either the β-blocker, ACEI, ARB theraphy, or just the ARB or ACEI theraphy). The characteristic of the 112 subject devide risk factors (age, gender, comorbidities include hypertension, diabetes mellitus, and dislipidemia). There was a substantial were relationship between the comorbids with the group given the either β-blocker, ACEI, ARB theraphy as well as the groups were treated with ACEI or ARB. Furthermore the independent T test indicated a significant result which signified a diffrence in the quality of life between those who received the β- blocker ACEI or ARB theraphy. Furthermore, through a Linear Regression Analysis the patients with ≥ 2 comorbidities showed a significant result (p ≤ 0,05). There was a significant difference on the quality of life between the patients with chronic heart failure treated either β-blocker ACEI or ARB (p ≤ 0,05).

Kata Kunci : Gagal Jantung Kronik, Kualitas Hidup, ACEI, ARB, β-blocker